Francis Averill, MD
Pulmonary Disease · Clearwater, FLNPI 1629005020
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $258,793 of the $367,288 with a category attached, or 70.5%. AstraZeneca accounts for 61.3% of it on its own, with 52 other manufacturers making up the rest. 2025 is the largest year on record at $101,646, more than ten times the $8,955 reported in 2019. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,420 payments — averaging $258.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$225K
- GSK$92K
- Insmed, Inc.$17K
- United Therapeutics Corporation$7K
- Harmony Biosciences LLC$6K
- Mannkind Corporation$3K
- plus $17K from 47 others
Across 1,413 payments — averaging $4201.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$1.7M
- Genentech, Inc.$691K
- AstraZeneca$480K
- E.r. Squibb & Sons, L.L.C.$435K
- Boehringer Ingelheim$342K
- GSK$340K
- plus $2M from 24 others
What the payments were for
- Consulting fees$23,2166%
- Speaking & faculty fees$258,79370%
- Travel & lodging$52,99114%
- Food & beverage$31,2309%
- Education$1,0580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$205,276
- TRELEGY ELLIPTA$52,109
- BREZTRI AEROSPHERE$6,343
- Wakix$4,544
- Arikayce$4,205
- TEZSPIRE$3,911
- SYMBICORT$2,825
- Olympus EBUS Bronchoscopes$2,175
- Olympus Capital Accessories$2,175
- Olympus Respiratory Accessories$2,175
- IMFINZI$1,636
- STIOLTO RESPIMAT$513
- TYVASO$352
- ARES HOME SLEEP TESTING DEVICE$280
- DUPIXENT$252
- NAVITOR$145
- Prolastin-C$126
- UPTRAVI$125
- TAGRISSO$125
- ORENITRAM$125
How this compares
$367,288 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 81 | $1,055,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 896 | $736,903 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 28 | $427,448 |
| Sodium Oxybate | 24 | $334,812 |
| Tyvaso DpiTreprostinil | 13 | $294,488 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 402 | $288,578 |
| AdempasRiociguat | 13 | $184,337 |
| XolairOmalizumab | 74 | $169,412 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 243 | $128,595 |
| Breo ElliptaFluticasone/Vilanterol | 223 | $112,111 |
| Fasenra PenBenralizumab | 20 | $110,952 |
| NucalaMepolizumab | 25 | $93,414 |
| TezspireTezepelumab-Ekko | 20 | $80,226 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 117 | $79,871 |
| Dupixent PenDupilumab | 19 | $77,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $2,334 | $1,217,602320 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $92,202 | $1,086,2331,427 claims |
| Insmed, Inc.Arikayce | $17,274 | $427,44828 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra | $225,329 | $415,389534 claims |
| BayerAdempas | $552 | $184,33713 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $242 | $13,47525 claims |
| PfizerEliquis | $24 | $9,61613 claims |
| Eisai Inc.Dayvigo | $183 | $7,98924 claims |
| MerckBelsomra | $148 | $7,27315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Clearwater
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.